A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac<sup>®</sup>) in India

Kulkarni, Prasad S.; Raut, Sidram; Dhere, Rajeev

doi:10.4161/hv.22317

Cited by 27 publications

(17 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Noted that these existing intranasal influenza vaccines are all cold adapted, but heat sensitive, allowing the viral replication in the nostrils but not in the lungs. Furthermore, the vaccines also display a good safety profile (88). Nasal vaccines based on inactivated or subunit vaccines remain difficult to commercialize.…”

Section: Route Of Administration Plays An Important Role In the Vaccimentioning

confidence: 99%

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

et al. 2020

View full text Add to dashboard Cite

In the race for a safe and effective vaccine against coronavirus disease (COVID)-19, pharmaceutical formulation science plays a critical role throughout the development, manufacturing, distribution, and vaccination phases. The proper choice of the type of vaccine, carrier or vector, adjuvant, excipients, dosage form, and route of administration can directly impact not only the immune responses induced and the resultant efficacy against COVID-19, but also the logistics of manufacturing, storing and distributing the vaccine, and mass vaccination. In this review, we described the COVID-19 vaccines that are currently tested in clinical trials and provided in-depth insight into the various types of vaccines, their compositions, advantages, and potential limitations. We also addressed how challenges in vaccine distribution and administration may be alleviated by applying vaccinestabilization strategies and the use of specific mucosal immune response-inducing, noninvasive routes of administration, which must be considered early in the development process.

show abstract

Section: Route Of Administration Plays An Important Role In the Vaccimentioning

confidence: 99%

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…FluMist Quadrivalent is a marketed nasal inhalation-based vaccine containing live attenuated influenza virus, which is sprayed into the nose to protect against influenza [62] . Another live attenuated vaccine Nasovac (Serum Institute of India Ltd.) is an intranasal vaccine against influenza A (H1N1) virus [63] .…”

Section: Novel Delivery Systems Targeting Respiratory Diseasesmentioning

confidence: 99%

Novel drug delivery systems and significance in respiratory diseases

Mishra

Singh

2020

Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems

View full text Add to dashboard Cite

“…Nasal delivery of vaccines allows for the convenience of administration and has the potential for inducing both mucosal and systemic immune responses [6]. Licensed intranasal vaccines for humans include the influenza vaccines, FluMist ® Quadrivalent (intranasal spray; MedImmune, Gaithersburg, MD, USA) and the Nasovac-S™ (intranasal spray; Cipla, Mumbai, India) [10,11]. In addition, several nasal delivery products are at various stages of development in the preclinical and clinical pipelines (Table 1).…”

Section: Introductionmentioning

confidence: 99%

Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting

et al. 2018

View full text Add to dashboard Cite

Most currently available commercial vaccines are delivered by systemic injection. However, needle-free oral vaccine delivery is currently of great interest for several reasons, including the ability to elicit mucosal immune responses, ease of administration, and the relatively improved safety. This review summarizes the biological basis, various physiological and immunological barriers, current delivery systems with delivery criteria, and suggestions for strategies to enhance the delivery of oral vaccines. In oral vaccine delivery, basic requirements are the protection of antigens from the GI environment, targeting of M cells and activation of the innate immune response. Approaches to address these requirements aim to provide new vaccines and delivery systems that mimic the pathogen’s properties, which are capable of eliciting a protective mucosal immune response and a systemic immune response and that make an impact on current oral vaccine development.

show abstract

A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac^®) in India

Cited by 27 publications

References 4 publications

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

Novel drug delivery systems and significance in respiratory diseases

Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting

Contact Info

Product

Resources

About

A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac®) in India

Cited by 27 publications

References 4 publications

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

Novel drug delivery systems and significance in respiratory diseases

Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting

Contact Info

Product

Resources

About

A post-marketing surveillance study of a human live-virus pandemic influenza A (H1N1) vaccine (Nasovac^®) in India